• Home
  • About
    • About Us
    • Executive Team
    • Board of Directors
    • Scientific Advisory Board
  • Pipeline
    • Overview
    • PAS-004
    • NF1
    • Presentations & Publications
  • Patients
    • Clinical Trials
    • Expanded Access
  • Investors
  • Contact

Pasithea Therapeutics Corp. to Present at the Benzinga Healthcare Small Cap Conference

by divibasicbldev | Sep 29, 2021 | Press Releases

MIAMI BEACH, Fla., Sept. 29, 2021 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric...

Pasithea Therapeutics Corp. Announces Closing of $24.0 Million Initial Public Offering

by divibasicbldev | Sep 17, 2021 | Press Releases

MIAMI BEACH, Fla., Sept. 17, 2021 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric...

Pasithea Therapeutics Corp. Announces Pricing of Upsized $24.0 Million Initial Public Offering

by divibasicbldev | Sep 15, 2021 | Press Releases

MIAMI BEACH, Fla., Sept. 14, 2021 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (“Pasithea” or the “Company”), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological...
Next Entries »

Recent Posts

  • Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference
  • Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences
  • Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026
  • Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit
  • Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion

Recent Comments

No comments to show.
Email Alerts

© Pasithea Therapeutics Corp. All Rights Reserved.